Category Archives: Uncategorized

Thus, loss of p-catenin limits cholestatic injury by modulating B

Thus, loss of p-catenin limits cholestatic injury by modulating BA biosynthesis through regulation of FXR. These findings support an important role of Wnt/p-catenin signaling in bile duct homeostasis and repair and provide novel therapeutic opportunity of modulating p-catenin signaling for alleviating BA-associated hepatic injury during cholestasis. Disclosures: Satdarshan

(Paul) S. Monga – Consulting: Bristol Myers Squibb, Phase Rx, Merck The following people have nothing to disclose: Kari Nejak-Bowen, Michael Thompson During DMXAA concentration cholestasis the balance between biliary growth/loss is regulated by neuroendocrine peptides and neurotransmitters by autocrine/paracrine and endocrine pathways. Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone (released from the hypothalamus) regulating reproductive functions in mammals. GnRH also alters the function of extra-pituitary non-reproductive organs such as the kidneys and pancreas. Since no data exists regarding the role of GnRH in regulating biliary homeostasis, we aimed to evaluate if GnRH regulates biliary growth in normal and bile duct ligated (BDL) rats by interacting with GnRH receptor (GnRHR). Methods: The studies were performed in: (i) normal rats treated with saline or GnRH (1 μg/day); BIBW2992 and (ii) BDL rats that, immediately after surgery, were treated with non-immune serum or anti-GnRH antibody (300μg/day) for

1 wk. Then, we measured: (i) intrahepatic bile duct mass (IBDM) in liver sections; and CK-19 and PCNA expression in total liver and cholangiocytes; and (ii) serum levels of GnRH by EIA kits. We measured the expression of: (i) GnRH and GnRHR in liver sections and cholangiocytes from normal and BDL rats and biliary lines by immunofluorescence, qPCR or immunoblots; and (ii) the levels of GnRH in the medium 上海皓元医药股份有限公司 of short-term (12 hr) cultures of cholangiocytes from normal and BDL rats and

biliary lines by EIA kits. In vitro, the: (i) dose- (10, 50 and 100 nM) and time- (24 to 72 hr) dependent effects of GnRH (in the absence/presence of the GnRHR antagonist, Cetrorelix acetate, 5-10 μM); and (ii) effect of Cetrorelix acetate (5-10 μM) on the proliferation of biliary lines was measured by MTS assays. GnRH expression was transiently knocked-down in biliary lines using siRNA and cell proliferation was assessed by MTS assays. Results: GnRH and GnRHR are expressed by normal bile ducts, cholangiocytes and biliary cell lines. GnRH biliary expression increased after BDL. Cholangiocytes secrete GnRH and, after BDL, GnRH secretion increased. Administration of GnRH to normal rats increased GnRH serum levels, biliary proliferation and IBDM, whereas administration of anti-GnRH antibody to BDL rats reduced biliary proliferation and IBDM. GnRH induced a dosedependent increase in biliary proliferation that was reduced by Cetrorelix acetate. Silencing of GnRH decreased the proliferation of biliary lines.

, MD (AASLD Postgraduate Course, Early Morning Workshops, Paralle

, MD (AASLD Postgraduate Course, Early Morning Workshops, Parallel Session) Consulting: GlaxoSmithKline, tibotec Grant/Research Support: Gilead, vertex, Ocera Forcione,

David G., MD (AASLD/ASGE Endoscopy Course) Nothing to disclose Content of the presentation does not include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s) Forns, Xavier, MD (Early Morning Workshops) Consulting: Tibotec/Jansen, MSD, Boheringher Ingelheim Grant/Research Support: Roche, MSD, Gilead Content of the presentation does not include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s) Fox, Ira J., MD (AASLD/NASPGHAN Pediatric Symposium) Advisory Committees or Review Panels: Regenerative Ensartinib clinical trial Medical Solutions Content of the presentation does not include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s) Franco, Jose, MD (Meet-the-Professor Luncheon) Nothing to disclose Content of the presentation

does not include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s)

Frenette, NVP-BGJ398 cost Catherine T., MD (Meet-the-Professor Luncheon) Speaking and Teaching: Onyx, Salix, Gilead Content of the presentation does not include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s) Fried, Michael W. MCE公司 (Parallel Session) Consulting: Genentech, Merck, Abbvie, Vertex, Janssen, Bristol Myers Squibb, Gilead Grant/Research Support: Genentech, Merck, AbbVie, Vertex, Janssen, Bristol Myers Squibb, Gilead Patent Held/Filed: HCCPlex Fried, Michael W., MD (AASLD Postgraduate Course, HCV Symposium) Advisory Committees or Review Panels: GlaxoSmithKline Consulting: Roche/Genentech, Janssen, Vertex, Merck, Bristol Myers Squibb, Abbott, Merck, Gilead, Novartis Grant/Research Support: Roche/Genentech, Janssen, Vertex, Merck, Bristol Myers Squibb, Abbott, Merck, Gilead Friedland, Shai, MD (AASLD/ASGE Endoscopy Course) Nothing to disclose Content of the presentation does not include discussion of off-label/investigative use of medicine(s), medical devices or procedure(s) Friedman, Joshua, MD, PhD (Early Morning Workshops, Parallel Session) Nothing to disclose Friedman, Lawrence S.

2%, 409% and 327%, respectively; significant differences in the

2%, 40.9% and 32.7%, respectively; significant differences in these values were noted between the groups (P = 0.03; Fig. 1). The 1-, 3- and 5-year recurrence-free survival rates for the HR Selleck R428 group were 85.1%, 64.8% and 48.6%, respectively, whereas those of the RF group were 29.0%, 7.2% and 7.2%, respectively; significant differences in these values were noted between the groups

(P = 0.0002; Fig. 2). Multivariate analysis was performed to identify the independent prognostic factors for survival and recurrence-free survival. We used factors of P ≤ 0.15 in the univariate analysis. For survival, these included AST (≥40 vs <40 IU/L), AFP (≥100 vs <100 ng/mL) and treatment (hepatic resection vs RFA). Moreover, for recurrence-free survival, these included the number of tumors (1 vs 2/3), AST (≥40 vs <40 IU/L), ALT (≥40 vs <40 IU/L), platelet count (≥10 vs <10 × 104/μL), prothrombin activity (≥85 vs <85%), DCP (≥100 vs <100 mAU/mL), ICG-R15 (≥20% vs <20%) and treatment. The results of the multivariate analysis are summarized in Table 2. RFA was the only independent risk factor for survival and recurrence-free survival for small, poorly differentiated HCC. THE TREATMENT STRATEGY for HCC is usually decided according to the tumor size,

tumor number, hepatic function and performance status. In general, RFA is considered to be better for treating Selleckchem Y27632 small HCC.[1, 2, 4] Thus, RFA is currently the first-line treatment for small HCC.[11, 12] RFA is currently indicated for tumors no larger

than 3 cm and in patients who have no more than three lesions.[7] For cases involving tumors no larger than 2 cm, the prognosis was found to be similar regardless of whether RFA or resection were used.[6] It has also been reported that RFA is effective for tumors larger than 3 cm,[13] although complications occur more frequently when RFA is used to treat these larger tumors.[14, 15] In addition to these findings, it has also been reported that RFA can be effectively used to treat recurrent tumors, metastatic tumors and unresectable tumors in the presence of cirrhosis.[5, 16-18] The risk factors for recurrence after RFA include a large tumor size, poor pathological differentiation 上海皓元 of tumor cells, an advanced tumor stage and young age.[9] Among the patterns of recurrence, tumor seeding is the most important, as it is associated with a poor prognosis.[19] It has been suggested that seeding is caused by preoperative biopsy,[20, 21] and it is also associated with a tumor location near the main portal branch, poor pathological differentiation of tumor cells, elevated AFP levels, and over-indication (i.e. ≥3 tumors, none of which are >3 cm).[8, 10, 22, 23] Moreover, a study of RFA reported that a subcapsular tumor location was also associated with tumor seeding.[24] However, other studies reported that subcapsular tumors should not be considered a contraindication for RFA[25] and, thus, the risk associated with subcapsular tumors remains unclear.

Two mandibular epoxy resin models (one for each implant system) w

Two mandibular epoxy resin models (one for each implant system) were fabricated, and two implants were inserted at the first and second molar region. Poly(vinyl siloxane) impression material was used to make the dental impression. For each implant system, fifteen models were fabricated, and each group was divided into three subgroups (group 1: titanium abutment with metal framework, group 2: titanium abutment with zirconium framework, group 3: zirconium abutment with zirconium framework). The replica technique was used to examine the marginal and internal gap values. For each restoration, 20 measurements

were performed, totaling 1200 measurements for all groups. Data were evaluated statistically using ANOVA and LSD post hoc find protocol test (p < 0.05). The highest values this website at internal adaptation measurements were found at the occlusal

surface for all groups. When the mean values of the marginal measurements were assessed, the lowest measurements were found in group 3 (51.416 μm), and the highest values were found in group 1 (79.394 μm). There were statistically significant differences between subgroups for marginal measurements (p < 0.05). As included in our study, marginal measurement values were found to be 46 to 87 μm. The marginal discrepancy of the tested materials could be considered clinically acceptable. ”
“Contemporary research in acrylic denture base materials focuses on the development of a novel poly(methyl methacrylate) (PMMA) resin with antimicrobial properties. Although PMMA resin has fulfilled all the requirements of an ideal denture base material,

its susceptibility to microbial colonization in the oral environment is a formidable concern to clinicians. Many mechanisms including the absence of ionic charge in the methyl methacrylate resins, hydrophobic interactions, electrostatic interactions, and mechanical attachment have been found 上海皓元 to contribute to the formation of biofilm. The present article outlines the basic categories of potential antimicrobial polymer (polymeric biocides) formulations (modified PMMA resins) and considers their applicability, biological status, and usage potential over the coming years. ”
“The aim of this systematic review was to compare straight-line and offset implant configurations for three-element implant-retained prostheses. Two independent reviewers conducted a review on PubMed/Medline, EMBASE, and Cochrane Library for studies published in English, from January 1, 1995 to January 17, 2014. A systematic review was conducted following the PRISMA statement. All relevant titles were selected according to inclusion/exclusion criteria. From this pool of titles, abstracts and full texts were reviewed. A total of 6080 titles were identified with the initial search. Twenty-one were selected based on title and abstract.

One of them developed telaprevir resistance (strain M) Telaprevi

One of them developed telaprevir resistance (strain M). Telaprevira protease inhibitor, acyl pyrrolidine a polymerase inhibitor and 2 candidate anti-polymerase drugs were tested. All these molecules had an IC50 < 100 nmol/L in HCV replicon and JFH1 models. Fresh PHH (fPHH) and cryopreserved PHH (cPHH) were obtained after liver resection

(Biopredic Inc, Rennes). All experiments were in triplicate or more. HCV RNA in cell culture and supernatant were measured by RT-PCR 3 days post inoculation. Results In fPHH, JFH1 lead to 3 to 4 log/μg at day 3. Using 7 different fPHH donors, only 3/39 HCVser lead to a low-level replication (log2-3) in more than one experiment. AZD6244 Using 4 different cPHH donors, 3 batches reproducibly permitted a log 4-5 viral load for 8/10 tested HCVser and for JFH1. TPV and pyrrolidine inhibited most HCVser (Genotype 1) with an IC50 which was 3 to 10-fold higher than those observed for replicon or JFH1. TPV resistance of the strain M was confirmed. The molecules A and B did not reduce the replication of any clinical strain in CPHH or in fPHH and

lead to hepatocytes necrosis. No clear relationship was found with IL28B genotype of PHH. Finally, the cellular mortality was lower for cPHH than check details forfPHH. Conclusion In the era of direct antiviral molecules, cPHH authorize a significant replication of different HCVser and reliably permit the comparison of different antiviral compounds on most natural HCV strains. A striking finding was that some compound could have an antiviral activity in artificial HCVcc models but not

in HCVser. Disclosures: Mehdi Lahmar – Employment: Vivalis/valneva The following people have nothing to disclose: Tony Durand, Patrice Bruscella, Claire Gondeau, Michel Ventura, Cyrille Feray Background: MK-5172, a reversible, non-covalent, competitive inhibitor of the hepatitis C MCE公司 virus (HCV) NS3/4A protease, is being developed for the treatment of chronic HCV infection. The aim of the study was to evaluate the potential pharmacokinetic (PK) interactions, as well as safety and tolerability of MK-5172, when co-administered with IV and oral rifampin (RIF) in healthy subjects. MK-5172 is a substrate of organic anion-transporting polypeptide (OATP) and breast cancer resistance protein (BCRP) in vitro and a CYP3A4/P-glycoprotein (P-gp) substrate in vivo. Rifampin is a potent inducer of CYP3A4/P-gp following multiple-dose administration, an inhibitor of P-gp with acute administration, and an inhibitor of OATP/BCRP. Therefore, the study also assessed the clinical significance of the OATP/BCRP and CYP3A4/P-gp pathways for MK-5172. Methods: This was an open-label, fixed-sequence, multiple-dose study in 12 healthy male and female volunteers, ages 19-55 years. In Period 1, subjects received a single intravenous (IV) dose of 600 mg RIF coadministered with a single oral dose of 200 mg MK-5172, followed by a 7-day washout.

When patients were asked: “if treatment was available would you b

When patients were asked: “if treatment was available would you be Autophagy inhibitors library interested,” all but 1 patient answered yes (95.2%). The survey also inquired about sex drive, and 32 patients responded to this question. Twenty-four patients (75%) reported a change in libido, 7 (21.9%) indicated no change, and 1 (3.1%) did

not respond to the question. Of those patients who reported a change in libido and responded to whether it occurred before or after their sexual pain began, 11 (68.7%) said it occurred after they developed sexual pain, 5 (31.2%) said it occurred before the sexual pain began, and 9 (56.25%) did not provide responses. We examined whether there was a significant association between whether patients reported pelvic pain brought on by, or preventing

sexual activity, and a change in libido. There was a marginally significant association between the presence of pelvic pain preventing sexual activity and change in libido χ2(1) = 2.84, P = .09, such that patients were more likely to report a change in libido (92.3%) if they indicated they had pelvic pain that prevented sexual activity compared with patients who did not (66.7%). To examine whether there was an association between the length of time patients suffered from pelvic pain and change in libido, a chi-square Angiogenesis inhibitor test of independence was conducted. No significant association was obtained, χ2(3) = 5.40, P > .05; however, the

MCE majority of patients who reported a change in sex drive indicated that they had pelvic pain between 1 and 5 years (43.5%). Only 4.3% of patients indicated a change in libido if they reported that they had pain for less than 1 year (26.1% fell in the 6-10 years and 10+ years categories each). For all chi-square tests indicated earlier, there were cells with an expected count less than 5, and therefore, the results should be interpreted with caution. Finally, patients were asked about whether they had a history of abuse or domestic violence. While most subjects did not report a history of abuse, 25% did. Sexual abuse was the most common, reported by 61.1% of these patients, followed by emotional abuse (55.6%) and physical abuse (33.3%). There was no association between the presence of pelvic pain, either brought on by or preventing sexual activity, and a history of abuse (physical, sexual or emotional), χ2(1) = 2.51, P > .05 and χ2(1) = 2.47, P > .05, respectively. The current study examined the prevalence of sexual pain in a sample of women presenting to a headache clinic with chronic headaches. Our findings demonstrate that 44% of women with headache report sexual pain either brought on by or preventing sexual activity.

8 experienced clinical decompensation compared to 16 (67%) of 23

8 experienced clinical decompensation compared to 16 (6.7%) of 238 with baseline AST/ALT ratio ≤0.8 (Table 2). Within each stratum of baseline AST/ALT ratio, patients who had severe worsening (>15% increase between month 24 and baseline) had a higher rate of clinical decompensation. The cumulative incidence of clinical decompensation at 3, 5, and 7 years is shown in Supporting Table 2C. Forty-eight (18.3%) of 263 patients

with baseline total bilirubin >0.7 mg/dL experienced clinical decompensation compared to 12 (5.8%) of 207 with baseline total bilirubin ≤0.7 mg/dL (Table 2). Within each stratum of baseline total bilirubin, patients who had severe worsening (>15% increase between month 24 and baseline) had a

higher rate of clinical decompensation. The cumulative incidence of clinical decompensation at 3, 5, and 7 years is shown in Supporting Table 2C. Forty-three (16.5%) of 261 patients with baseline albumin see more ≤3.9 mg/dL experienced clinical decompensation compared to 17 (8.1%) of 209 with baseline albumin >3.9 mg/dL (Table 2). Within each stratum GDC-0449 clinical trial of baseline albumin, patients who had severe worsening (>15% decrease between month 24 and baseline) had a higher rate of clinical decompensation. The cumulative incidence of clinical decompensation at 3, 5, and 7 years is shown in Supporting Table 2C. A multivariate model including baseline platelet count, AST/ALT ratio, bilirubin, and albumin (Model IA) showed that each of these four baseline laboratory values independently predicted the occurrence of clinical decompensation (Table 3A). A model including changes in values of these four laboratory tests between month 24 and baseline (Model IIA) found that severe worsening (>15% change) but not mild worsening (5%-15% change) of platelet count, bilirubin, as well as albumin were independent predictors of clinical

decompensation, whereas changes in 上海皓元医药股份有限公司 AST/ALT ratio were not. Inclusion of both baseline laboratory values and changes in laboratory values (Model IIIA) showed that baseline platelet, AST/ALT ratio, and bilirubin; and severe worsening of platelet count, bilirubin, and albumin were independent predictors of clinical decompensation. Model IIIA has the lowest AIC (621), indicating that it has a better fit than Model IA (AIC: 651) and Model IIA (AIC: 655). Addition of age, gender, and race did not improve the fit of any of these models. The duration of follow-up was similar among the three categories of change for each variable irrespective of whether the variable was normal or abnormal at baseline and did not impact the accuracy of the model. To address the issue whether a longer observation period would have any effect on the accuracy of the model, we used change in laboratory values from baseline to month 48 (Table 2B), and compared the results with those obtained using change in laboratory values from baseline to month 24.

1B) However, all treatments increased serum alkaline phosphatase

1B). However, all treatments increased serum alkaline phosphatase (ALP) levels (Fig. 1B) (modest increase by INT-767) and liver weight/body weight (LW/BW) ratio (Supporting Fig. 1A). http://www.selleckchem.com/products/atezolizumab.html Histological examination (i.e., hematoxylin and eosin [H&E] staining) of INT-767-treated Mdr2−/− mouse livers showed less portal inflammation and bile duct proliferation (Fig. 1C), compared with untreated mice. In contrast, INT-747 aggravated liver damage in Mdr2−/− mice, as reflected

by increased bile duct proliferation, portal tract expansion (Fig. 1C), and single-cell necrosis with lobular inflammation (Supporting Fig. 1B), whereas no significant changes were detected after treatment with INT-777. INT-767 treatment reduced F4/80, tumor necrosis factor alpha (Tnf-α), and interleukin BVD-523 order (Il)-1β messenger RNA (mRNA) levels (Fig. 2A-C) as well as the number of cluster of differentiation (CD)-11b- and F4/80-positive cells (Supporting Fig. 2A,B). In contrast, INT-747 increased Il-1β mRNA levels (Fig. 2C) and portal CD-11b-positive cell accumulation in Mdr2−/− mice (Supporting Fig. 2A). The reactive cholangiocyte

phenotype was also reduced by INT-767, as reflected by significantly lowered K19 and vascular cell adhesion molecule-1 (Vcam-1) mRNA levels and by immunohistochemical staining (Supporting Fig. 3). INT-747 increased Vcam-1 and monocyte chemotactic protein 1 (Mcp-1) mRNA levels and induced Vcam-1 staining in cholangiocytes, MCE inflammatory cell infiltrates, and periportal

hepatocytes, whereas INT-777 increased only Mcp-1 mRNA levels (Supporting Fig. 3). Liver fibrosis was reduced in INT-767-treated Mdr2−/− mice, as reflected by hepatic hydroxyproline (HP) content, inhibition of collagen type 1 alpha 1 (Col1a1) gene expression, and reduced spleen weight (SW)/BW ratio (Fig. 2D-F). In contrast, HP, Col1a1 mRNA, as well as SW/BW ratio increased in INT-747-fed mice, but remained unchanged in INT-777-fed mice. These findings were also confirmed by Sirius red staining (Supporting Fig. 4). Ki-67 staining revealed increased hepatocyte proliferation by INT-767 and INT-747 in Mdr2−/− (data not shown) and Fxr+/+ mice, but not in Fxr−/− mice (Supporting Fig. 5). Potential direct anti-inflammatory and antifibrotic effects of INT-767 were addressed in macrophage, cholangiocyte, and hepatocyte cell lines and isolated primary myofibroblasts (MFBs). Notably, despite the potent in vivo effects, INT-767 had only a modest or not statistically significant effect on lipopolysaccharide-induced Il-6 expression in RAW264.7 macrophages, Tnf-α-induced Vcam-1 gene expression in biliary epithelial cells (BEC), and TNF-α−induced TNF-α gene expression in HepG2 cells, despite pronounced inhibition of cholesterol 7 alpha-hydroxylase (CYP7A1) as a positive control (Supporting Fig. 6).

They underwent a gastrectomy with standard lymphadenectomy One d

They underwent a gastrectomy with standard lymphadenectomy. One day before surgery, 99mtechnetium-tin colloid was endoscopically injected into the submucosa around the tumor. After surgery, the uptake of radioisotope in dissected lymph nodes was measured using Navigator GPS. Then, all dissected lymph nodes were investigated by hematoxylin-eosin staining and immunohistochemistry using an antihuman cytokeratin monoclonal antibody. Hematoxylin-eosin staining demonstrated lymph node metastasis in two (12.5%) of 16 patients and in three (0.8%) of 382 nodes. However, immunohistochemistry Selinexor solubility dmso showed that none of the patients had lymph node micrometastasis.

Sentinel nodes (SNs) were identified in all patients. The mean number of SNs was 3.1 (range, 1–6). Among two patients with lymph node metastasis, the SNs, at least, contained positive nodes. Accordingly, the false-negative and accuracy rates were 0% and 100%, respectively. Our results indicate that SNNS may have potential as a further minimally invasive surgery in early gastric cancer patients after noncurative endoscopic resection. ”
“Chronic diseases of the biliary

system are common and may cause fibrosis and eventually progression to liver cirrhosis. The aim was to define a new mouse XAV-939 mw model of a cholangiopathy leading to liver fibrosis in fra-1tg mice. Liver pathology of fra-1tg mice was analyzed in detail by histology and flow cytometry. Transcript levels of fibrosis-related genes and matrix metalloproteinase (MMP) activities were quantified and immunohistochemical analysis additionally applied. The role of the immune system in this model was analyzed by crossing fra-1tg mice with rag2−/− mice. Furthermore, expression of Fra-1 in corresponding human liver diseases was investigated on transcription level and histologically. Fra-1tg mice spontaneously 上海皓元 develop biliary fibrosis preceded by ductular proliferation and infiltration of inflammatory cells. Fra-1 protein

is present in cholangiocytes and inflammatory cells within the liver. These findings were replicated in human biopsies of patients with advanced liver fibrosis. The inflammatory infiltrate showed a strong increase in activated T cells and decreased natural killer (NK), natural killer T cells (NKT), and B cells in fra-1tg mice as compared to wildtype mice. Moreover, fra-1tg mice develop biliary fibrosis with a time-dependent increase in hepatic collagen content and increase in relative messenger RNA (mRNA) expression of profibrotic genes. Attenuation but not complete prevention of collagen accumulation in liver was observed in the fra-1tg × rag2−/− mice. However, transplantation of fra-1tg bone marrow cells into wildtype mice could not induce disease. Conclusion:Fra-1tg mice spontaneously develop a progressive biliary disease.

These 5 patients showed all remained HCC viable tissue, 1 patient

These 5 patients showed all remained HCC viable tissue, 1 patient showed 4week MRI positive finding and the other 4 patients showed

12week MRI positive. On the contrary, among patient who showed 4week CT scan positive without 4week CEUS positive, no one finally diagnosed as having viable HCC positive. Especially, among 8 patients of 4week CEUS positive, 4 patients (50%) did not presented 4week MRI positive and they all finally confirmed to have remained HCC tissue just by 12week MRI test. Conclusions: In assessment see more of therapeutic response of TACE, early 4week CEUS showed excellent result in diagnosis and prediction of remained viable HCC. However, this result was derived from just small samples as preliminary study and has to be followed by more advanced well designed large population study. Keywords: Hepatocellular carcinoma, transarterial chemoembolization, contrast-enhanced ultrasonography Disclosures: The following people

have nothing to disclose: Moon Young Kim, Soon Koo Baik, Mee-Yon Cho, Youn Zoo Cho, Won Ki Hong, Hye Won Hwang, Jin Hyung Lee, Myeong Hun Chae, Seung Yong Shin, Jung Min Kim, Erlotinib research buy Sang Ok Kwon, Dong Joon Kim, Ki Tae Suk, Gab Jin Cheon, Dae Hee Choi Hadrien Dyvorne1, Guido H. Jajamovich1,M. Isabel Fiel1, Scott L. Friedman1, Douglas T. Dieterich1, Claudia Donnerhack1, Richard Ehman2, Bachir Taouli1 1Icahn School of Medicine at Mount Sinai, New York, NY; 2Mayo Clinic, Rochester, MN Introduction To assess the diagnostic value of multiparametric MRI including diffusion-weighted imaging (DWI), dynamic contrast-enhanced MRI (DCE MRI), MR elastography (MRE), compared to transient elastography (TE) for detection of liver fibrosis. Methods This study was approved by the local IRB and all subjects gave informed consent upon enrollment.48 subjects underwent MRI and TE exams.48 subjects were enrolled (9 volunteers and 39 with chronic liver disease). DWI was performed using 16 b values and diffusion decay was fitted to the intravoxel incoherent motion model to yield D (true diffusion),

PF (perfusion fraction), D* (pseudo diffusion) and ADC (apparent diffusion). DCE MRI was acguired after gadolinium contrast injection and a dual input single compartment model to yield arterial, portal and hepatic flow (Fa, Fp, Ft), arterial 上海皓元医药股份有限公司 fraction (ART), distribution volume (DV), mean transit time (MTT) and time to peak (TTP). Liver stiffness was measured with MRE (LSMRE) and TE (LS-TE). Comparisons between noninvasive modal-ities and fibrosis METAVIR stages findings on histopathology were performed using Spearman correlation. ROC analysis was performed to assess the performance of each technigue for the detection of moderate (F2-F4) or advanced (F3-F4) fibrosis. Results Correlations with fibrosis stage were significant for D (r =-0.58, p<0.001), ADC (r = -0.50, p=0.001), MTT (r = 0.44, p=0.011), TTP (r = 0.47, p=0.005), LS-MRE (r = 0.77, p<0.001) and LS-TE (r = 0.66, p<0.001).